Chronic Kidney Disease

Empagliflozin Reduced Risk of Renal Disease Progression, CV Death Across CKD Spectrum in EMPA-KIDNEY
November 07, 2022

Empagliflozin achieved a decrease in risk of kidney disease progression of 28% vs placebo in the most diverse population of patients in an SGLT-2 inhibitor trial.

Finerenone Mitigates HF, CV Risk Across Baseline Renal Function in Patients with T2D
October 27, 2022

The findings underscore the importance of routine eGFR and UACR screening in primary care to ensure early detection of CKD and avoid related adverse outcomes.

PCPs, Cardiologists May Not Adequately Stratify, Treat CV Risk in Patients with Type 2 Diabetes
October 19, 2022

CMHC. PCPs and cardiologists appeared to perform only half of items considered necessary for care of T2D patients in a new simulated patient study.

Cardiometabolic Disease Update: 12 Studies
October 12, 2022

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

Primary Care Would Benefit from Education on Use of SGLT-2 Inhibitors, GLP-1 Mimetics: Nisa Maruthur, MD, MHS
October 05, 2022

Dr Maruthur, a primary care physician, helped develop the new ADA/EASD consensus report on T2D management and has suggestions.

ADA, EASD 2022 Consensus Report from the Primary Care Point of View, with Nisa Maruthur, MD, MHS
October 03, 2022

Dr Maruthur, of Johns Hopkins Medicine, talks about how the concept of "holistic" patient care continues to expand in the management of persons with T2D.

ADA, EASD Release Update on Management of Hyperglycemia in Type 2 Diabetes
September 23, 2022

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Nocturnal Hypertension: 8 Essential Questions
September 14, 2022

Nocturnal HTN is a risk factor for cardiovascular disease and stroke. How do you diagnose and treat in your practice? Test your overnight BP IQ.

Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
September 14, 2022

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

Comorbidity Burden in T2D Patients Varies Widely, Becomes More Diverse Over Time
August 11, 2022

Analysis of 224 000 type 2 diabetes patients over 2 decades suggests the need for "revised care pathways" that better reflect the myriad causes of persistent morbidity.